Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.

PMID:
19620143
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y; Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators.

AIDS. 2012 Jan 2;26(1):45-56. doi: 10.1097/QAD.0b013e32834dce6e.

PMID:
22008655
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.

AIDS. 2007 Jul;21 Suppl 4:S117-28.

PMID:
17620747
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The cost effectiveness of combination antiretroviral therapy for HIV disease.

Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ.

N Engl J Med. 2001 Mar 15;344(11):824-31.

PMID:
11248160
[PubMed - indexed for MEDLINE]
Free Article
5.

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA; Cepac US And Actg A5164 Investigators.

HIV Clin Trials. 2010 Sep-Oct;11(5):248-59. doi: 10.1310/hct1105-248.

PMID:
21126955
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.

Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR 3rd, Cohen MS, Freedberg KA.

N Engl J Med. 2013 Oct 31;369(18):1715-25. doi: 10.1056/NEJMsa1214720.

PMID:
24171517
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The cost-effectiveness of preventing AIDS-related opportunistic infections.

Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, Paltiel AD.

JAMA. 1998 Jan 14;279(2):130-6. Erratum in: JAMA 1999 Jun 2;281(21):1989.

PMID:
9440663
[PubMed - indexed for MEDLINE]
8.

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire JH, Gibb DM, Babiker AG.

Lancet. 2010 Apr 10;375(9722):1278-86. doi: 10.1016/S0140-6736(10)60057-8. Epub 2010 Mar 27.

PMID:
20347483
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
[PubMed - indexed for MEDLINE]
10.

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.

Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA; Global AIDS Policy Model Investigators.

AIDS. 2005 Aug 12;19(12):1299-308.

PMID:
16052085
[PubMed - indexed for MEDLINE]
11.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.

N Engl J Med. 2006 Sep 14;355(11):1141-53.

PMID:
16971720
[PubMed - indexed for MEDLINE]
Free Article
13.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD004772.

PMID:
22786492
[PubMed - indexed for MEDLINE]
14.

Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.

Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.

Cochrane Database Syst Rev. 2013 Oct 10;10:CD010309. doi: 10.1002/14651858.CD010309.pub2. Review.

PMID:
24114324
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.

Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ.

Arch Intern Med. 2002 Nov 25;162(21):2478-86.

PMID:
12437408
[PubMed - indexed for MEDLINE]
16.

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC.

Ann Intern Med. 2008 Feb 5;148(3):178-85.

PMID:
18252681
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa.

Abimbola TO, Marston BJ.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):e8-e14. doi: 10.1097/QAI.0b013e3182478dc0.

PMID:
22240461
[PubMed - indexed for MEDLINE]
18.

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Long EF, Brandeau ML, Owens DK.

Ann Intern Med. 2010 Dec 21;153(12):778-89. doi: 10.7326/0003-4819-153-12-201012210-00004.

PMID:
21173412
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.

Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Bärnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group.

Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230.

PMID:
23880306
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP; CEPAC-International and OCTANE Investigators.

AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe.

PMID:
21293199
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk